RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Kappa opioid receptor antagonists are provided that yield
significant improvements in functional binding assays to kappa
opioid receptors relative to nor-BNI, and the use of these
antagonists in treatment of disease states that are ameliorated by
binding of the kappa opioid receptor such as heroin or cocaine
addictions.